INSIDE THE LAB / FAQ
Questions Answered Straight From the Trial Record
Direct, citation-anchored answers to the questions readers most often bring to these four compounds.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide that activates the ghrelin receptor on pituitary cells, triggering a pulse of growth hormone release. It was engineered from an older, less selective compound (GHRP-1) specifically to avoid raising cortisol and prolactin, which its founding characterization confirmed even at doses far above what triggers growth hormone release [5]. Research-labelled ipamorelin is still sold for laboratory work; a prescription request goes to a licensed provider for review and a prescribing decision. Ipamorelin has no FDA drug approval; FDA keeps ipamorelin acetate in Category 2 for 503B compounding, citing safety concerns.
What does ipamorelin do for you?
In its founding animal work, ipamorelin reliably triggers a single growth-hormone pulse from the pituitary and, in rats, increased longitudinal bone growth rate in a dose-dependent way over 15 days [5]. In its one published human trial — surgical patients recovering from bowel resection — it sped the return of normal gut function numerically but not by a statistically significant margin [3]. In a 2024 ferret model, it reduced chemotherapy-associated weight loss by around 24% during the delayed recovery phase, though it had no effect on the nausea that came with it [1]. There is no published trial testing ipamorelin's effects in a healthy person outside a specific medical context.
What are the risks of ipamorelin?
The most-cited theoretical risks come from mechanism rather than a direct ipamorelin study: growth-hormone-axis stimulation raises IGF-1, a hormone linked to cell growth, so active or recent cancer is flagged as a caution despite no ipamorelin-specific cancer data existing [5]. Ipamorelin also has a direct effect on pancreatic insulin release independent of growth hormone, which complicates its likely effect on blood sugar in anyone with existing glucose problems. A 28-day safety study of a related ghrelin-receptor compound (not ipamorelin itself) found dose-dependent heart-muscle damage in rats — a class-level warning worth taking seriously precisely because no equivalent long-term study of ipamorelin exists [2]. Outside its one short surgical trial, there is no published long-term human safety data for ipamorelin at all [3].
What is KPV peptide?
KPV is a three-amino-acid peptide — lysine, proline, valine — that corresponds to the tail end of a larger natural hormone, alpha-melanocyte-stimulating hormone (alpha-MSH). It keeps that hormone's anti-inflammatory effect while dropping its pigment-darkening action. It is small enough to enter intestinal cells through a dedicated transporter, PepT1, which is part of why so much of the KPV literature focuses on gut inflammation [8].
What does KPV peptide do?
In repeated mouse studies, KPV reduces colitis severity — measured by faster recovery, less inflammatory tissue damage, and lower levels of inflammatory signaling molecules — whether the colitis is triggered chemically or through a chronic immune-transfer model [8][9]. Outside the gut, topical KPV completely healed corneal wounds in every treated rabbit eye within 60 hours, versus none in the untreated group [11]. Mechanistically, it works by suppressing NF-kB and MAP-kinase inflammatory signaling in cells [8][10]. As of this writing, none of this has been confirmed in a published human trial.
What is KPV peptide used for?
In the published research literature, KPV has been studied almost entirely as an anti-inflammatory agent in animal models of inflammatory bowel disease, with additional work in corneal wound healing and a peritonitis model [8][9][11][12]. A substantial share of recent research is not testing new effects of KPV at all, but engineering better ways to deliver it — nanoparticle and hydrogel formulations designed to keep the fragile tripeptide intact long enough to reach inflamed tissue [6][7]. Research-labelled KPV remains on sale for laboratory work, while prescription requests require review and a decision by a licensed provider. KPV has no FDA drug approval or dietary-supplement status.
What does the MOTS-c peptide do?
In mouse studies, MOTS-c activates AMPK, a cellular energy sensor, which improves how muscle cells take up and use glucose [15]. It directly binds an enzyme called CK2, activating it in muscle (helping prevent muscle wasting) while apparently suppressing it in fat tissue [13]. Given to mice of various ages, exogenous MOTS-c measurably boosted treadmill endurance and grip strength, with the largest gains seen in aged mice [16]. In one human cohort study, higher circulating MOTS-c levels in hemodialysis patients were independently associated with lower combined risk of death and cardiovascular events [14] — an association in existing blood levels, not a test of giving someone the peptide.
What are the negative side effects of MOTS-c?
There is no published human trial of giving someone exogenous MOTS-c, so there is no clinical adverse-event data to report. The cautions that exist are structural rather than symptomatic: no measured human pharmacokinetics exist, so mouse research doses (typically several milligrams per kilogram daily) cannot be responsibly scaled to a human amount; laboratory-labelled material still lacks a pharmaceutical purity standard, while prescription requests require a licensed provider's review and decision; and a specific mitochondrial DNA variant has been linked in the literature to a less favorable metabolic response and to ancestry-dependent differences in exercise benefit, suggesting effects may not be uniform across people with different mitochondrial genetics.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any human use and carries no dietary-supplement status. Laboratory-labelled MOTS-c is still sold for research; that label does not describe prescription care. This page does not evaluate suppliers or recommend sources; prescription access turns on a licensed provider's review of the individual request and the decision that follows. The papers reviewed here do not establish human dosing or verify product purity, and compounded medications are not FDA-approved.
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide, and the first approved medicine to activate two hormone receptors — GIP and GLP-1 — with a single molecule. A long fatty-acid side chain lets it bind loosely to albumin in the blood, stretching its presence in the body to roughly five days and enabling once-weekly dosing. It is FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity [19].
How does tirzepatide work?
By activating both the GIP and GLP-1 receptors at once, tirzepatide gets the pancreas to release insulin only when blood sugar is actually elevated, slows how quickly the stomach empties, and turns down glucagon, a hormone that would otherwise raise blood sugar. In the brain, the same dual signaling reaches appetite circuits, reducing hunger and the food-related mental preoccupation some patients describe as "food noise." Laboratory work found tirzepatide engages the GIP receptor more strongly than the GLP-1 receptor and signals through the GLP-1 receptor with a biased profile that researchers believe helps explain its added benefit over single-receptor drugs, though the full mechanism is still being worked out [19].
What is tirzepatide used for?
FDA-approved uses are type 2 diabetes mellitus (approved May 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity [19]. In trials, it produced average weight reductions up to 20.9% over 72 weeks at its highest dose [21], and in a direct head-to-head comparison outperformed an established single-receptor GLP-1 medicine, 20.2% versus 13.7% weight loss [18]. It remains a prescription medicine and is not evaluated on this desk for off-label or non-prescribed use.